Results: << | 101-125 | 126-150 | 151-175 | 176-200 | >>

Table of contents of journal: *Alimentary pharmacology and therapeutics

Results: 126-150/1697

Authors: Talley, NJ Van Zanten, SV Saez, LR Dukes, G Perschy, T Heath, M Kleoudis, C Mangel, AW
Citation: Nj. Talley et al., A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia, ALIM PHARM, 15(4), 2001, pp. 525-537

Authors: Basson, MD Panzini, L Palmer, RH
Citation: Md. Basson et al., Effect of nabumetone and aspirin on colonic mucosal bleeding time, ALIM PHARM, 15(4), 2001, pp. 539-542

Authors: Labayen, I Forga, L Gonzalez, A Lenoir-Wijnkoop, I Nutr, R Martinez, JA
Citation: I. Labayen et al., Relationship between lactose digestion, gastrointestinal transit time and symptoms in lactose malabsorbers after dairy consumption, ALIM PHARM, 15(4), 2001, pp. 543-549

Authors: Hadziyannis, AS Papaioannou, C Spanou, F Manesis, EK Hadziyannis, SJ
Citation: As. Hadziyannis et al., Induction interferon therapy in nave patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit, ALIM PHARM, 15(4), 2001, pp. 551-557

Authors: Waldum, HL Brenna, E
Citation: Hl. Waldum et E. Brenna, On gastric polyps, proton pump inhibitors and long-term risks - Reply, ALIM PHARM, 15(4), 2001, pp. 559-560

Authors: Humphries, TJ
Citation: Tj. Humphries, On gastric polyps, proton pump inhibitors and long-term risks, ALIM PHARM, 15(4), 2001, pp. 559-559

Authors: Guslandi, M
Citation: M. Guslandi, Nicotine-induced NO release in colitis, ALIM PHARM, 15(4), 2001, pp. 560-561

Authors: Schwrer, H Lorf, T Ringe, B Ramadori, G
Citation: H. Schwrer et al., Pantoprazole and cyclosporine or tacrolimus, ALIM PHARM, 15(4), 2001, pp. 561-562

Authors: Green, J Richardson, C Marshall, R Rhodes, J McKirdy, H Thomas, G Williams, G
Citation: J. Green et al., Nicotine-induced NO release in colitis - Reply, ALIM PHARM, 15(4), 2001, pp. 561-561

Authors: Fitzgerald, RC Lascar, R Triadafilopoulos, G
Citation: Rc. Fitzgerald et al., Barrett's oesophagus, dysplasia and pharmacologic acid suppression, ALIM PHARM, 15(3), 2001, pp. 269-276

Authors: Camilleri, M
Citation: M. Camilleri, Review article: tegaserod, ALIM PHARM, 15(3), 2001, pp. 277-289

Authors: Tripathi, D Hayes, PC
Citation: D. Tripathi et Pc. Hayes, Review article: A drug therapy for the prevention of variceal haemorrhage, ALIM PHARM, 15(3), 2001, pp. 291-310

Authors: Barr, H Dix, AJ Kendall, C Stone, N
Citation: H. Barr et al., Review article: The potential role for photodynamic therapy in the management of upper gastrointestinal disease, ALIM PHARM, 15(3), 2001, pp. 311-321

Authors: Dove-Edwin, I Thomas, HJW
Citation: I. Dove-edwin et Hjw. Thomas, Review article: The prevention of colorectal cancer, ALIM PHARM, 15(3), 2001, pp. 323-336

Authors: Chamberlin, W Graham, DY Hulten, K El-Zimaity, HMT Schwartz, MR Naser, S Shafran, I El-Zaatari, FAK
Citation: W. Chamberlin et al., Review article: Mycobacterium avium subsp paratuberculosis as one cause ofCrohn's disease, ALIM PHARM, 15(3), 2001, pp. 337-346

Authors: Talley, NJ Lauritsen, K Tunturi-Hihnala, H Lind, T Moum, B Bang, C Schulz, T Omland, TM Delle, M Junghard, O
Citation: Nj. Talley et al., Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6months, ALIM PHARM, 15(3), 2001, pp. 347-354

Authors: Poynard, T Regimbeau, C Benhamou, Y
Citation: T. Poynard et al., Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome, ALIM PHARM, 15(3), 2001, pp. 355-361

Authors: Herrlinger, KR Noftz, MK Fellermann, K Schmidt, K Steinhoff, J Stange, EF
Citation: Kr. Herrlinger et al., Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use, ALIM PHARM, 15(3), 2001, pp. 363-369

Authors: Ierardi, E Principi, M Francavilla, R Pisani, A Rendina, M Ingrosso, M Guglielmi, FW Panella, C Francavilla, A
Citation: E. Ierardi et al., Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance, ALIM PHARM, 15(3), 2001, pp. 371-377

Authors: Sanduleanu, S Jonkers, D De Bruine, A Hameeteman, W Stockbrugger, RW
Citation: S. Sanduleanu et al., Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa, ALIM PHARM, 15(3), 2001, pp. 379-388

Authors: Shirin, H Kenet, G Shevah, O Wardi, Y Birkenfeld, S Shahmurov, M Bruck, R Niv, Y Moss, SF Avni, Y
Citation: H. Shirin et al., Evaluation of a novel continuous real time C-13 urea breath analyser for Helicobacter pylori, ALIM PHARM, 15(3), 2001, pp. 389-394

Authors: Costa, F Mumolo, MG Bellini, M Romano, MR Manghetti, M Paci, A Maltinti, G Marchi, S
Citation: F. Costa et al., Post-treatment diagnostic accuracy of a new enzyme immunoassay to detect Helicobacter pylori in stools, ALIM PHARM, 15(3), 2001, pp. 395-401

Authors: Wong, BCY Wong, WM Wang, WH Fung, FMY Lai, KC Chu, KM Yuen, ST Leung, SY Hu, WHC Yuen, MF Lau, GKK Chan, CK Lam, SK
Citation: Bcy. Wong et al., One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance, ALIM PHARM, 15(3), 2001, pp. 403-409

Authors: Fakheri, H Malekzadeh, R Merat, S Khatibian, M Fazel, A Alizadeh, BZ Massarrat, S
Citation: H. Fakheri et al., Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate, ALIM PHARM, 15(3), 2001, pp. 411-416

Authors: Nagahara, A Miwa, H Yamada, T Kurosawa, A Ohkura, R Sato, N
Citation: A. Nagahara et al., Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection, ALIM PHARM, 15(3), 2001, pp. 417-421
Risultati: << | 101-125 | 126-150 | 151-175 | 176-200 | >>